Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders

Neurology

Volumn 83, Issue 13, 2014, Pages 1210-1216

  Gnanapavan, Sharmilee ^a   Hegen, Harald ^b   Khalil, Michael ^c   Hemmer, Bernhard ^d   Franciotta, Diego ^e   Hughes, Steve ^f   Hintzen, Rogier ^g   Jeromin, Andreas ^h   Havrdova, Eva ⁱ   Tumani, Hayrettin ^j   Bertolotto, Antonio ^k   Comabella, Manuel ^l   Frederiksen, Jette ^m   Álvarez Cermeño, José C ⁿ   Villar, Luisa ⁿ   Galimberti, Daniela ^o   Myhr, Kjell Morten ^p   Dujmovic, Irena ^q   Fazekas, Franz ^c   Ionete, Carolina ^r   Menge, Til ^s   Kuhle, Jens ^u   Keir, Geoffrey ^a   Deisenhammer, Florian ^b   Teunissen, Charlotte ^t   Giovannoni, Gavin ^u   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^f ISIS PHARMACEUTICALS   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h Quanterix Inc   (United States)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j UNIVERSITY HOSPITAL ULM   (Germany)

^k SAN LUIGI GONZAGA HOSPITAL   (Italy)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

ⁿ HOSPITAL RAMÓN Y CAJAL   (Spain)

^o UNIVERSITY OF MILAN   (Italy)

^p UNIVERSITY OF BERGEN   (Norway)

^q UNIVERSITY OF BELGRADE   (Serbia)

^r UMASS MEMORIAL MEDICAL CENTER   (United States)

^s HEINRICH HEINE UNIVERSITY   (Germany)

^t VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^u QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BODY FLUID; COMORBIDITY; DISEASE ACTIVITY; HUMAN; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; CHEMISTRY; MEDICAL RESEARCH; METABOLISM; RESEARCH; STANDARDS;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; BODY FLUIDS; HUMANS; NERVOUS SYSTEM DISEASES; PRACTICE GUIDELINES AS TOPIC; RESEARCH REPORT;

EID: 84921743474     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000809     Document Type: Review

References (36)

1. Ahmed AA, Brenton JD. Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. Breast Cancer Res 2005;7:96-99.
2. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998;52:289-303.
3. Riley RD, Abrams KR, Sutton AJ, et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 2003;88:1191-1198.
4. Panteghini M. Recent approaches in standardization of cardiac markers. Clin Chim Acta 2001;311:19-25.
5. Baker M. In biomarkers we trust? Nat Biotechnol 2005; 23:297-304.
6. Wilkins MR, Appel RD, Van Eyk JE, et al. Guidelines for the next 10 years of proteomics. Proteomics 2006;6:4-8.
7. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009;73:1914-1922.
8. Teunissen CE, Tumani H, Bennett JL, et al. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int 2011;2011:246412.
9. Teunissen C, Menge T, Altintas A, et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013;19:1802-1809.
10. Group BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
11. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229-235.
12. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Ann Intern Med 2003; 138:40-44.
13. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285:1987-1991.
14. Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:1259-1271.
15. LaBaer J. So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res 2005; 4:1053-1059.
16. Dumas ME, Canlet C, Debrauwer L, Martin P, Paris A. Selection of biomarkers by a multivariate statistical processing of composite metabonomic data sets using multiple factor analysis. J Proteome Res 2005;4:1485-1492.
17. Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol 2004;15:1731-1737.
18. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-2317.
19. Bustin SA. Absolute quantification of mRNA using realtime reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169-193.
20. Bast RC Jr, Lilja H, Urban N, et al. Translational crossroads for biomarkers. Clin Cancer Res 2005;11: 6103-6108.
21. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005;34:215-220.
22. Rifai N, Watson ID, Miller WG. Commercial immunoassays in biomarkers studies: researchers beware! Clin Chem 2012;58:1387-1388.
23. Valentin MA, Ma S, Zhao A, Legay F, Avrameas A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J Pharm Biomed Anal 2011;55:869-877.
24. Hofler M. The Bradford Hill considerations on causality: a counterfactual perspective. Emerg Themes Epidemiol 2005;2:11.
25. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 2008;17:303-340.
26. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440.
27. Rauer S, Euler B, Reindl M, Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006;77:739-742.
28. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease: Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998;338:506-511.
29. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011;305:1322-1326.
30. Smith MJ, Esparza S, Merker VL, et al. Plasma S100beta is not a useful biomarker for tumor burden in neurofibromatosis. Clin Biochem 2012;46:698-700.
31. Costine BA, Quebeda-Clerkin PB, Dodge CP, Harris BT, Hillier SC, Duhaime AC. Neuron-specific enolase, but not S100B or myelin basic protein, increases in peripheral blood corresponding to lesion volume after cortical impact in piglets. J Neurotrauma 2012;29:2689-2695.
32. Vandenbroucke JP. STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK. and CONSORT: for whom does the guideline toll? J Clin Epidemiol 2009;62:594-596.
33. Nesvizhskii AI, Aebersold R. Analysis, statistical validation and dissemination of large-scale proteomics datasets generated by tandem MS. Drug Discov Today 2004;9:173-181.
34. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. JAMA 2000;283:2008-2012.
35. Taylor CF, Field D, Sansone SA, et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigation: the MIBBI project. Nat Biotechnol 2008;26: 889-896.
36. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354(9193):1896-1900.